Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Lly save search
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Published: 2022-04-11 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 37.7%
H: 143.24%
C: 105.01%
covid-19 drug sabizabulin phase 3
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Published: 2021-01-27 (Crawled : 12:00) - globenewswire.com
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -1.12%
H: 0.1%
C: -1.6%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.78%
H: 0.45%
C: -1.66%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -7.13%
H: 96.21%
C: 15.59%
covid ev biotech trial
Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
Published: 2023-10-31 (Crawled : 10:00) - globenewswire.com
VERV | News | $6.64 -0.3% -0.3% 1.1M
|
Professional, Scientific, and T...
|
| O: 5.31%
H: 28.36%
C: 21.49%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.03%
H: 0.0%
C: 0.0%
Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients
Published: 2022-04-25 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.29%
H: 2.58%
C: 2.31%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.89%
H: 27.06%
C: 24.67%
covid-19 treatment sabizabulin presentation phase 2
Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-11-10 (Crawled : 02:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.09%
H: 0.48%
C: 0.4%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -58.83%
H: 25.89%
C: 12.78%
covid-19 fda risk sabizabulin meeting respiratory authorization update
Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
Published: 2022-12-05 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.27%
H: 0.4%
C: -1.2%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -1.82%
H: 20.93%
C: 7.78%
year financial results
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
Published: 2022-07-06 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.85%
H: 1.45%
C: 0.66%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.26%
H: 20.43%
C: 12.73%
covid-19 treatment sabizabulin trial results publication phase 3
AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-08-04 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.0%
H: 5.72%
C: 2.53%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: 2.61%
H: 20.19%
C: 14.8%
ACIU | $2.375 -0.21% -0.21% 320K
|
Health Technology
|
| O: -1.54%
H: 4.56%
C: 0.0%
financial results results
Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS
Published: 2022-06-07 (Crawled : 11:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -2.57%
H: 17.21%
C: 13.21%
covid-19 fda risk drug antiviral application authorization emergency use authorization
Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors
Published: 2021-07-19 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.03%
H: 1.04%
C: 0.97%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.68%
H: 0.41%
C: -0.31%
PRLD | $3.81 10.76% 9.71% 58K
|
Health Technology
|
| O: -2.4%
H: 15.87%
C: 11.88%
Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
solid tumors results trial trial results
Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
treatment phase 1 injection results cancer colorectal cancer phase 1b phase 2b
Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
heart positive results trial
AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 07:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
heart positive results trial
DTx Pharma Appoints Jill Howe as Chief Financial Officer
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
pharma
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
Published: 2022-12-22 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.55%
PRQR | News | $1.965 5.65% 5.34% 130K
|
Health Technology
|
| O: 64.85%
H: 13.97%
C: -0.74%
axiomer conference platform
Lilly and ProQR to Expand RNA Editing Collaboration
Published: 2022-12-22 (Crawled : 12:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.55%
PRQR | News | $1.965 5.65% 5.34% 130K
|
Health Technology
|
| O: 64.85%
H: 13.97%
C: -0.74%
collaboration
Lilly and ProQR to Expand RNA Editing CollaborationNew agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR’s Axiomer technology
Published: 2022-12-22 (Crawled : 13:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.55%
PRQR | News | $1.965 5.65% 5.34% 130K
|
Health Technology
|
| O: 64.85%
H: 13.97%
C: -0.74%
axiomer technology agreement
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
Published: 2023-11-29 (Crawled : 04:00) - globenewswire.com
VERV | News | $6.64 -0.3% -0.3% 1.1M
|
Professional, Scientific, and T...
|
| O: -11.15%
H: 13.21%
C: 5.66%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
offering therapeutics
Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
Published: 2023-11-28 (Crawled : 21:00) - globenewswire.com
VERV | News | $6.64 -0.3% -0.3% 1.1M
|
Professional, Scientific, and T...
|
| O: -11.15%
H: 13.21%
C: 5.66%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
offering therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.